ADMA 📈 ADMA Biologics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0008991046
ADMA: Immune Globulin, Hepatitis B Vaccine, Plasma-Derived Therapeutics
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Web URL: https://www.admabiologics.com
Additional Sources for ADMA Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ADMA Stock Overview
Market Cap in USD | 4,494m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2013-10-17 |
ADMA Stock Ratings
Growth 5y | 73.2% |
Fundamental | 88.8% |
Dividend | - |
Rel. Strength Industry | 2975 |
Analysts | 4.8/5 |
Fair Price Momentum | 20.01 USD |
Fair Price DCF | 8.67 USD |
ADMA Dividends
No Dividends PaidADMA Growth Ratios
Growth Correlation 3m | 14.5% |
Growth Correlation 12m | 96.3% |
Growth Correlation 5y | 65.4% |
CAGR 5y | 32.66% |
CAGR/Mean DD 5y | 0.92 |
Sharpe Ratio 12m | 2.40 |
Alpha | 290.17 |
Beta | 0.73 |
Volatility | 67.34% |
Current Volume | 6941.5k |
Average Volume 20d | 2772.6k |
What is the price of ADMA stocks?
As of December 21, 2024, the stock is trading at USD 17.40 with a total of 6,941,535 shares traded.
Over the past week, the price has changed by -6.40%, over one month by -18.58%, over three months by -12.91% and over the past year by +325.43%.
As of December 21, 2024, the stock is trading at USD 17.40 with a total of 6,941,535 shares traded.
Over the past week, the price has changed by -6.40%, over one month by -18.58%, over three months by -12.91% and over the past year by +325.43%.
Is ADMA Biologics a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, ADMA Biologics (NASDAQ:ADMA) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 88.84 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADMA as of December 2024 is 20.01. This means that ADMA is currently undervalued and has a potential upside of +15% (Margin of Safety).
Yes, based on ValueRay Fundamental Analyses, ADMA Biologics (NASDAQ:ADMA) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 88.84 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADMA as of December 2024 is 20.01. This means that ADMA is currently undervalued and has a potential upside of +15% (Margin of Safety).
Is ADMA a buy, sell or hold?
ADMA Biologics has received a consensus analysts rating of 4.80. Therefor, it is recommend to buy ADMA.
ADMA Biologics has received a consensus analysts rating of 4.80. Therefor, it is recommend to buy ADMA.
- Strong Buy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for ADMA stock price target?
According to ValueRays Forecast Model, ADMA ADMA Biologics will be worth about 22 in December 2025. The stock is currently trading at 17.40. This means that the stock has a potential upside of +26.67%.
According to ValueRays Forecast Model, ADMA ADMA Biologics will be worth about 22 in December 2025. The stock is currently trading at 17.40. This means that the stock has a potential upside of +26.67%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 23.5 | 34.8% |
Analysts Target Price | 6 | -65.5% |
ValueRay Target Price | 22 | 26.7% |